Munich, Germany - 26 Aug 2018: A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI 61 trial1 presented today in a Hot Line Session at ESC Congress2 and published in the New England Journal of Medicine.
Lorcaserin is an appetite suppressant, increasing the sense of fullness after a meal and reducing hunger before meals. It is not approved as a weight loss drug in Europe. The European Medicines Agency has expressed concerns about the potential risk of tumours based on animal data, psychiatric disorders including depression, and problems with heart valves.
The US Food and Drug Administration (FDA) in June 2012 approved the medication for weight loss in overweight adults with a body mass index (BMI) of 30 kg/m2 or greater, or with a BMI of 27 kg/m2 or greater and at least one weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol. As with all weight loss agents, the FDA's approval was contingent on postmarketing studies assessing the risk for major adverse cardiovascular events.
The CAMELLIA-TIMI 61 trial was conducted as part of the FDA's postmarketing requirement. The trial examined the safety and efficacy of the drug with regard to major adverse cardiovascular events (MACE) and progression to diabetes in overweight or obese individuals with, or at risk for, cardiovascular disease.
The trial enrolled 12,000 adults from 473 centres in eight countries between January 2014 and November 2015. Participants had a BMI of at least 27 kg/m2 and either 1) established cardiovascular disease3 (with or without diabetes) or 2) diabetes and at least one other cardiovascular risk factor.4 Participants were randomly allocated in a 1:1 ratio to lorcaserin (10 mg twice a day) or matching placebo. All participants were advised to exercise and eat healthily.
The primary safety endpoint was noninferiority of the drug compared to placebo for MACE (cardiovascular death, myocardial infarction, or stroke) after 460 events had occurred. If the safety endpoint was met, the trial would proceed to completion and assess the primary efficacy endpoint of superiority of the drug for MACE plus hospitalisation for unstable angina, heart failure, or any coronary revascularisation. Secondary endpoints included delay or prevention of conversion to type 2 diabetes in those with pre-diabetes at baseline, and the effect on weight, heart rate, blood pressure, lipids, and blood sugar.
The average age of participants was 64 years, 64% were male, and the median BMI was 35 kg/m2. Three-quarters (8,958; 75%) had a history of at least one established cardiovascular disease: 8,153 (68%) had coronary artery disease, 1,129 (9.4%) had cerebrovascular disease, and 657 (5.5%) had peripheral artery disease. More than half (57%) had diabetes, 90% had hypertension, 94% had hyperlipidaemia, and 20% had renal insufficiency.
The interim analysis after 460 events showed that the trial met its primary safety objective. At study completion with a median follow-up of 3.3 years, MACE occurred in 6.1% of those taking lorcaserin and 6.2% of those on placebo, demonstrating noninferiority (p<0.001).
The trial did not meet its superiority endpoint. The composite of MACE plus hospitalisation for unstable angina, heart failure, or any coronary revascularisation occurred in 11.8% of participants taking the drug and 12.1% of those on placebo (p=0.55).
On top of lifestyle counselling, those taking lorcaserin lost an average of 4.2 kg in the first year compared to 1.4 kg for those taking placebo (p<0.001). At one year, 39% of those taking the drug had lost at least 5% of their body weight compared to 17% of the placebo group (p<0.001) while 15% on the drug lost 10% of their body weight compared to 5% on placebo (p<0.001). The differences between groups remained statistically significant at 3.3-years of follow-up.
Regarding secondary endpoints, compared to placebo, the medication reduced the conversion rate to diabetes in participants with pre-diabetes at baseline. The drug also led to small improvements in levels of triglycerides, blood glucose, heart rate and blood pressure.
In the CAMELLIA-TIMI 61 study, the most common side effects possibly related to the drug and leading to drug discontinuation were dizziness, fatigue, headache and nausea - all of which are listed on the FDA-approved label. There was no difference in the occurrence of malignancy between the drug and placebo groups. In a dedicated echocardiographic substudy, there was a non-significant imbalance in the incidence of valvular disease at one year between the drug and placebo groups (1.8% versus 1.3%; p=0.24). Serious hypoglycaemia was more common in patients on lorcaserin, a side effect observed in prior studies.
Lorcaserin is not approved for use in women who are pregnant, breastfeeding, or planning to become pregnant. It should be used with caution in patients with congestive heart failure. If signs or symptoms of valvular heart disease develop, such as dyspnoea or a new cardiac murmur, patients should be evaluated and discontinuation of the drug considered. People taking the drug should be monitored for depression, changes in mood, and suicidal thoughts or behaviours - the drug should be discontinued if the latter are experienced.
"We have been able to show for the first time that this weight loss drug does what it is intended to do. It helps people lose weight without causing an increase in major adverse cardiovascular events in a population at higher risk for heart attacks and strokes," said Dr Erin Bohula, an investigator with the CAMELLIA-TIMI 61 trial and TIMI Study Group investigator at Brigham and Women's Hospital, Boston, US.
"One of our hypotheses was that losing weight with this medication might also lead to a cardiovascular benefit but we did not see that," she continued. "While there were improvements in multiple cardiovascular risk factors, including weight, lipids and blood glucose, the magnitude of impact on these risk factors was relatively small."
Dr Bohula said: "Nevertheless, the CAMELLIA-TIMI 61 study is notable as it provides the first demonstration of cardiovascular safety of any weight loss agent in a dedicated cardiovascular outcomes trial."
Notes to editors
Notes to editors
SOURCES OF FUNDING: Eisai Inc.
DISCLOSURES: Dr Bohula has received personal fees from Servier, Merck, NIH, Lexicon, Medscape, Academic CME, MD Conference Express, Paradigm, and Novartis, and grants from Amgen, Astra Zeneca, and Merck.
1CAMELLIA-TIMI 61: Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 Trial.
2CAMELLIA-TIMI 61 will be discussed during:
* Press Conference - Hot Line - Late Breaking Clinical Trials 1 on Sunday 26 August at 08:00 CEST.
* Hot Line Session 1 on Sunday 26 August at 14:30 to 15:45 CEST in the Munich Auditorium.
* Meet the Trialist - CAMELLIA-TIMI 61 on Sunday 26 August at 16:20 to 16:40 CEST on the ESC TV Stage in ESC Plaza.
3 Established cardiovascular disease was defined as history of documented myocardial infarction or ischaemic stroke, history of peripheral artery disease, history of revascularisation (coronary, carotid, or peripheral artery), or significant unrevascularised coronary arterial stenosis.
4 Cardiovascular risk factors were defined as hypertension, dyslipidaemia, creatinine clearance greater than 30-60 mL/min using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, elevated high sensitivity C-reactive protein, or urinary albumin-to-creatinine ratio (ACR) 30 μg/mg or greater.
About the European Society of Cardiology
The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.
About ESC Congress 2018
ESC Congress is the world's largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2018 takes place 25 to 29 August at the Messe München in Munich, Germany. Explore the scientific programme.
More information is available from the ESC Press Office at firstname.lastname@example.org.